Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy

Abstract

The polo-like kinase 1 (PLK1) acts in concert with cyclin-dependent kinase 1–cyclin B1 and Aurora kinases to orchestrate a wide range of critical cell cycle events. Because PLK1 has been preclinically validated as a cancer target, small-molecule inhibitors of PLK1 have become attractive candidates for anticancer drug development. Although the roles of the… (More)
DOI: 10.1038/nrd3184

Topics

5 Figures and Tables